Literature DB >> 25047959

Development and retrospective validation of the juvenile spondyloarthritis disease activity index.

Pamela F Weiss1, Robert A Colbert, Rui Xiao, Chris Feudtner, Timothy Beukelman, Esi Morgan DeWitt, Ilaria Pagnini, Tracey B Wright, Carol A Wallace.   

Abstract

OBJECTIVE: To develop and validate the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) for use in clinical practice and research.
METHODS: Using modified Delphi consensus techniques, 10 items were selected by participants in the international pediatric rheumatology listserv, the Childhood Arthritis and Rheumatology Research Alliance, and the listserv for the pediatric section of the American College of Rheumatology. Validation was performed in a retrospective multicenter cohort of 244 children.
RESULTS: In total, 106 physicians representing 14 countries completed the initial questionnaire. Completion rates for the subsequent questionnaires were 84%, 75%, and 77% of the original respondents. Ten items exceeded 80% consensus: arthritis, enthesitis, patient pain assessment, inflammatory markers, morning stiffness, clinical sacroiliitis, uveitis, back mobility, and patient and physician assessments of disease activity. After item analysis, 2 items were eliminated (patient and physician assessments of disease activity). Factor analysis identified 3 primary domains that explained 58% of the variance: peripheral disease, axial disease, and uveitis. The Cronbach's α coefficient was 0.66. The JSpADA had high or moderate correlations with the Juvenile Arthritis Disease Activity Score (r = 0.81), patient and physician assessments of disease activity (r = 0.70 and r = 0.66, respectively), and the Childhood Health Assessment Questionnaire (r = 0.56). The JSpADA discriminated well between subjects with active versus inactive disease (P < 0.001) and was responsive to improvement or worsening in disease activity over time (P < 0.001).
CONCLUSION: Using international input and consensus formation techniques, we developed and validated the first disease activity assessment for juvenile spondyloarthritis. Future studies should validate the JSpADA in a prospective multicenter cohort.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 25047959      PMCID: PMC4245319          DOI: 10.1002/acr.22411

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  28 in total

1.  A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies.

Authors:  R Burgos-Vargas; J Vázquez-Mellado; C Pacheco-Tena; A Hernández-Garduño; M V Goycochea-Robles
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

2.  Design and validation of a new scale to assess the functional ability in children with juvenile idiopathic arthritis (JIA).

Authors:  M J Iglesias; R J Cuttica; M Herrera Calvo; M Micelotta; A Pringe; M I Brusco
Journal:  Clin Exp Rheumatol       Date:  2006 Nov-Dec       Impact factor: 4.473

3.  Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy.

Authors:  B Flatø; A Aasland; O Vinje; O Førre
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

4.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

5.  Juvenile chronic arthritis into adulthood: a long-term follow-up study.

Authors:  M Zak; F K Pedersen
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

6.  Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Authors:  Marieke H Otten; Femke H M Prince; Marinka Twilt; Rebecca Ten Cate; Wineke Armbrust; Esther P A H Hoppenreijs; Yvonne Koopman-Keemink; Nico M Wulffraat; Simone L Gorter; Koert M Dolman; Joost F Swart; J Merlijn van den Berg; Marion A J van Rossum; Lisette W A van Suijlekom-Smit
Journal:  J Rheumatol       Date:  2011-08-15       Impact factor: 4.666

7.  Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study.

Authors:  Anne M Selvaag; Gunhild Lien; Dag Sørskaar; Odd Vinje; Øystein Førre; Berit Flatø
Journal:  J Rheumatol       Date:  2005-06       Impact factor: 4.666

8.  Epidemiology of spondyloarthritis in North America.

Authors:  John D Reveille
Journal:  Am J Med Sci       Date:  2011-04       Impact factor: 2.378

9.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

Authors:  Alessandro Consolaro; Nicolino Ruperto; Anna Bazso; Angela Pistorio; Silvia Magni-Manzoni; Giovanni Filocamo; Clara Malattia; Stefania Viola; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2009-05-15

10.  Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Authors:  Gerd Horneff; Ruben Burgos-Vargas; Tamas Constantin; Ivan Foeldvari; Jelena Vojinovic; Vyacheslav G Chasnyk; Joke Dehoorne; Violeta Panaviene; Gordana Susic; Valda Stanevica; Katarzyna Kobusinska; Zbigniew Zuber; Richard Mouy; Ingrida Rumba-Rozenfelde; Luciana Breda; Pavla Dolezalova; Chantal Job-Deslandre; Nico Wulffraat; Daniel Alvarez; Chuanbo Zang; Joseph Wajdula; Deborah Woodworth; Bonnie Vlahos; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2013-05-21       Impact factor: 19.103

View more
  22 in total

1.  Assessment of Sacroiliitis at Diagnosis of Juvenile Spondyloarthritis by Radiography, Magnetic Resonance Imaging, and Clinical Examination.

Authors:  Pamela F Weiss; Rui Xiao; David M Biko; Nancy A Chauvin
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

2.  Prominent midfoot involvement in children with enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  Sanat Phatak; Namita Mohindra; Abhishek Zanwar; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2017-06-20       Impact factor: 2.980

Review 3.  Juvenile spondyloarthritis.

Authors:  Sabrina Gmuca; Pamela F Weiss
Journal:  Curr Opin Rheumatol       Date:  2015-07       Impact factor: 5.006

4.  Paediatric rheumatology: A disease activity index for juvenile SpA-a welcome addition.

Authors:  Roberta A Berard; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

Review 5.  Juvenile Spondyloarthropathies.

Authors:  Amra Adrovic; Kenan Barut; Sezgin Sahin; Ozgur Kasapcopur
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

6.  Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.

Authors:  Pamela F Weiss; Rui Xiao; Timothy G Brandon; Ilaria Pagnini; Tracey B Wright; Timothy Beukelman; Esi Morgan-DeWitt; Chris Feudtner
Journal:  J Rheumatol       Date:  2017-09-15       Impact factor: 4.666

7.  Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  A Shukla; P Gaur; A Aggarwal
Journal:  Clin Exp Immunol       Date:  2016-09       Impact factor: 4.330

8.  Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis.

Authors:  Ayşenur Paç Kısaarslan; Betül Sözeri; Zübeyde Gündüz; Gökmen Zararsız; Hakan Poyrazoğlu; Ruhan Düşünsel
Journal:  Eur J Rheumatol       Date:  2019-04-22

Review 9.  Enthesitis-related arthritis.

Authors:  Amita Aggarwal; Durga Prasanna Misra
Journal:  Clin Rheumatol       Date:  2015-08-02       Impact factor: 2.980

Review 10.  Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.

Authors:  Erkan Demirkaya; Alessandro Consolaro; Hafize Emine Sonmez; Gabriella Giancane; Dogan Simsek; Angelo Ravelli
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.